ConductScience.org, home

Trial · NCT02787304

Results by group76

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Number of Subjects Achieving Binary Response on Liver Histology Between Volixibat (SHP626) and Placebo at Week 48SHP626 5 Milligram (mg)4Participants
Number of Subjects Achieving Binary Response on Liver Histology Between Volixibat (SHP626) and Placebo at Week 48SHP626 10 Milligram (mg)2Participants
Number of Subjects Achieving Binary Response on Liver Histology Between Volixibat (SHP626) and Placebo at Week 48SHP626 20 Milligram (mg)3Participants
Number of Subjects Achieving Binary Response on Liver Histology Between Volixibat (SHP626) and Placebo at Week 48Placebo (PBO)5Participants
Change From Baseline to Week 48 on Liver HistologySHP626 5 Milligram (mg)NAS - steatosis-0.5Standard Deviation 0.82score on a scale
Change From Baseline to Week 48 on Liver HistologySHP626 10 Milligram (mg)NAS - steatosis-0.2Standard Deviation 0.87score on a scale
Change From Baseline to Week 48 on Liver HistologySHP626 20 Milligram (mg)NAS - steatosis-0.5Standard Deviation 0.93score on a scale
Change From Baseline to Week 48 on Liver HistologyPlacebo (PBO)NAS - steatosis-0.3Standard Deviation 0.85score on a scale
Change From Baseline to Week 48 on Liver HistologySHP626 5 Milligram (mg)NAS - ballooning-0.3Standard Deviation 0.9score on a scale
Change From Baseline to Week 48 on Liver HistologySHP626 10 Milligram (mg)NAS - ballooning-0.2Standard Deviation 0.75score on a scale
Change From Baseline to Week 48 on Liver HistologySHP626 20 Milligram (mg)NAS - ballooning0.0Standard Deviation 0.93score on a scale
Change From Baseline to Week 48 on Liver HistologyPlacebo (PBO)NAS - ballooning-0.7Standard Deviation 0.85score on a scale
Change From Baseline to Week 48 on Liver HistologySHP626 5 Milligram (mg)NAS - inflammation-0.2Standard Deviation 0.75score on a scale
Change From Baseline to Week 48 on Liver HistologySHP626 10 Milligram (mg)NAS - inflammation-0.5Standard Deviation 0.93score on a scale
Change From Baseline to Week 48 on Liver HistologySHP626 20 Milligram (mg)NAS - inflammation-0.5Standard Deviation 0.76score on a scale
Change From Baseline to Week 48 on Liver HistologyPlacebo (PBO)NAS - inflammation-0.7Standard Deviation 0.95score on a scale
Change From Baseline to Week 48 on Hepatic SteatosisSHP626 5 Milligram (mg)-2.68Standard Deviation 4.801absolute percentage
Change From Baseline to Week 48 on Hepatic SteatosisSHP626 10 Milligram (mg)-1.31Standard Deviation 7.555absolute percentage
Change From Baseline to Week 48 on Hepatic SteatosisSHP626 20 Milligram (mg)-3.89Standard Deviation 4.474absolute percentage
Change From Baseline to Week 48 on Hepatic SteatosisPlacebo (PBO)-1.34Standard Deviation 5.478absolute percentage

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02787304/results